Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 20 of 20 results for aflibercept

  1. Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)?

    associated with inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs....

  2. Past appeals and decisions

    raltitrexed 8 January 2002 TA307 Colorectal cancer (metastatic) – aflibercept 23 January 2014 TA118 Colorectal cancer (metastatic) -...

  3. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

  4. Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

    This evidence summary has been replaced by NICE technology appraisal guidance 486.  

  5. Thousands of people in England could benefit after NICE recommends treatment option for two forms of sight loss

    NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema